|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Bücklein, Veit; Perez, Ariel; Rejeski, Kai; Iacoboni, Gloria; Jurinovic, Vindi; Holtick, Udo; Penack, Olaf; Kharboutli, Soraya; Blumenberg, Viktoria; Ackermann, Josephine; Frölich, Lisa; Johnson, Grace; Patel, Kedar; Arciola, Brian; Mhaskar, Rahul; Wood, Anthony; Schmidt, Christian; Albanyan, Omar; Gödel, Philipp; Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Mackensen, Andreas; Locke, Frederick; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Barba, Pere; Subklewe, Marion und Jain, Michael D.
(2023):
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
In: HemaSphere, Bd. 7, Nr. 8, e907
ORCID: https://orcid.org/0000-0002-0749-1389; Bullinger, Lars; Mackensen, Andreas; Locke, Frederick; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Barba, Pere; Subklewe, Marion und Jain, Michael D.
(2023):
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
In: HemaSphere, Bd. 7, Nr. 8, e907
Rejeski, Kai ORCID: https://orcid.org/0000-0003-3905-0251; Wang, Yucai ORCID: https://orcid.org/0000-0002-1576-8341; Albanyan, Omar; Munoz, Javier; Sesques, Pierre ORCID: https://orcid.org/0000-0001-8264-822X; Iacoboni, Gloria; Lopez‐Corral, Lucia; Ries, Isabelle; Bücklein, Veit L.; Mohty, Razan; Dreyling, Martin; Baluch, Aliyah; Shah, Bijal ORCID: https://orcid.org/0000-0003-4328-6021; Locke, Frederick L.; Hess, Georg; Barba, Pere; Bachy, Emmanuel; Lin, Yi; Subklewe, Marion ORCID: https://orcid.org/0000-0001-9154-9469 und Jain, Michael D. ORCID: https://orcid.org/0000-0002-7789-1257
(2023):
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
In: American Journal of Hematology, Bd. 98, Nr. 11: S. 1699-1710
[PDF, 2MB]
ORCID: https://orcid.org/0000-0003-3905-0251; Wang, Yucai ORCID: https://orcid.org/0000-0002-1576-8341; Albanyan, Omar; Munoz, Javier; Sesques, Pierre ORCID: https://orcid.org/0000-0001-8264-822X; Iacoboni, Gloria; Lopez‐Corral, Lucia; Ries, Isabelle; Bücklein, Veit L.; Mohty, Razan; Dreyling, Martin; Baluch, Aliyah; Shah, Bijal ORCID: https://orcid.org/0000-0003-4328-6021; Locke, Frederick L.; Hess, Georg; Barba, Pere; Bachy, Emmanuel; Lin, Yi; Subklewe, Marion ORCID: https://orcid.org/0000-0001-9154-9469 und Jain, Michael D. ORCID: https://orcid.org/0000-0002-7789-1257
(2023):
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
In: American Journal of Hematology, Bd. 98, Nr. 11: S. 1699-1710
[PDF, 2MB]